Table 4.
Clinical studies, antimicrobial therapies, and outcomes for patients infected with KPC-producing K. pneumoniae
| Reference | Country (yr of publication) | Study design | No. of patients with indicated infection | Type of β-lactamase (no. of isolates) | Treatment with active drug (no. of patients) | Outcome (no. of successes/no. of failures) |
|---|---|---|---|---|---|---|
| 252 | Colombia (2006) | Case reports | 23 (10 BSIs, 10 pneumonias, 1 endocarditis, 1 liver abscess, 1 empyema) | KPC-2 (19) | Carbapenem (4) | 3/1 |
| 153 | USA (2006) | KPC-3 (2) | Colistin (3) | 2/1 | ||
| 257 | China (2007) | KPC-type enzyme (2) | Tigecycline (1) | 0/1 | ||
| 71 | USA (2007) | Aminoglycoside (2) | 1/1 | |||
| 6 | USA (2008) | Tigecycline-colistin (2) | 1/1 | |||
| 162 | China (2008) | Tigecycline-aminoglycoside (1) | 1/0 | |||
| 81 | USA (2008) | Colistin-aminoglycoside (1) | 1/0 | |||
| 159 | USA (2009) | Aminoglycoside-fluoroquinolone (1) | 1/0 | |||
| 17 | Israel (2009) | Carbapenem-aminoglycoside (1) | 1/0 | |||
| 158 | USA (2009) | No active drug (7) | 1/6 | |||
| 80 | USA (2009) | |||||
| 116 | USA (2010) | |||||
| 138 | Brazil (2011) | |||||
| 52 | Taiwan (2011) | |||||
| 10 | Switzerland (2011) | |||||
| 113 | USA (2011) | |||||
| 25 | USA (2004) | Case series | 4 (1 BSI, 2 urinary tract infections [UTIs], 1 pneumonia) | KPC-2 (4) | Carbapenem (1) | 1/0 |
| Carbapenem-colistin (1) | 1/0 | |||||
| Carbapenem-aminoglycoside (1) | 1/0 | |||||
| Colistin (1) | 0/1 | |||||
| 258 | USA (2009) | Case series | 21 (5 pneumonias, 5 BSIs, 4 cases of tracheobronchitis, 5 UTIs, 1 case of meningitis, 1 surgical site infection [SSI]) | KPC-3 (21) | Carbapenem (4) | 2/2 |
| Tigecycline (5) | 4/1 | |||||
| Aminoglycoside (3) | 3/0 | |||||
| Carbapenem-tigecycline (1) | 0/1 | |||||
| Tigecycline-aminoglycoside (1) | 1/0 | |||||
| No active drug (7) | 3/4 | |||||
| 154 | Greece (2009) | Case series | 13 (9 pneumonias, 4 BSIs) | KPC-2 (13) | Aminoglycoside (2) | 2/0 |
| Tigecycline-colistin (8) | 6/2 | |||||
| Colistin-aminoglycoside (3) | 3/0 | |||||
| 83 | USA (2009) | Case series | 7 (3 BSIs, 1 UTI, 3 urinary colonizations) | KPC-2 (1) | Colistin (1) | 0/1 |
| KPC-3 (6) | Colistin-aminoglycoside (2) | 0/2 | ||||
| No active drug (4) | 0/4 | |||||
| 182 | USA (2009) | Case series | 3 BSIs | KPC-2 (3) | Tetracycline-aminoglycoside (1) | 1/0 |
| Colistin (3) | 1/2 | |||||
| 237 | Greece (2010) | Case series | 17 (11 BSIs, 2 SSIs, 1 UTI, 2 pneumonias, 1 case of cholangitis) | KPC-2 (17) | Colistin (11) | 6/5 |
| Tigecycline (1) | 1/0 | |||||
| Aminoglycoside (1) | 1/0 | |||||
| Colistin-aminoglycoside (2) | 1/1 | |||||
| Tigecycline-colistin-aminoglycoside (1) | 1/0 | |||||
| No active drug (1) | 1/0 | |||||
| 175 | Greece (2010) | Case-control study | 19 BSIs | KPC-2 (19) | Colistin (10) | 2/8 |
| Colistin-aminoglycoside (9) | 4/5 | |||||
| 274 | Greece (2011) | Case-control study | 53 BSIs | KPC-2 (53) | Carbapenem (1) | 0/1 |
| Colistin (7) | 3/4 | |||||
| Tigecycline (5) | 3/2 | |||||
| Aminoglycoside (2) | 2/0 | |||||
| Colistin-aminoglycoside (2) | 2/0 | |||||
| Carbapenem-aminoglycoside (1) | 1/0 | |||||
| Tigecycline-colistin (9) | 9/0 | |||||
| Tigecycline-aminoglycoside (4) | 4/0 | |||||
| Carbapenem-tigecycline (1) | 1/0 | |||||
| Carbapenem-tigecycline-colistin (2) | 2/0 | |||||
| Tigecycline-colistin-aminoglycoside (1) | 1/0 | |||||
| No active drug (18) | 7/11 |